Cerity Partners LLC Acquires New Stake in ProPhase Labs, Inc. (NASDAQ:PRPH)

Cerity Partners LLC acquired a new stake in ProPhase Labs, Inc. (NASDAQ:PRPH) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 94,113 shares of the company’s stock, valued at approximately $38,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. HighTower Advisors LLC grew its holdings in ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after acquiring an additional 57,736 shares during the period. Geode Capital Management LLC grew its holdings in ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after acquiring an additional 42,793 shares during the period. Perritt Capital Management Inc grew its holdings in ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after acquiring an additional 107,068 shares during the period. Renaissance Technologies LLC grew its holdings in ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after acquiring an additional 71,375 shares during the period. Finally, Warberg Asset Management LLC acquired a new stake in ProPhase Labs during the 4th quarter worth about $77,000. 9.45% of the stock is currently owned by institutional investors and hedge funds.

ProPhase Labs Stock Performance

Shares of ProPhase Labs stock opened at $0.36 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.98 and a debt-to-equity ratio of 0.30. The business has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $0.38. ProPhase Labs, Inc. has a 1-year low of $0.22 and a 1-year high of $3.23. The company has a market cap of $14.78 million, a P/E ratio of -0.28 and a beta of -0.41.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings results on Tuesday, May 20th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.06. The business had revenue of $1.43 million for the quarter, compared to analyst estimates of $2.45 million. As a group, analysts anticipate that ProPhase Labs, Inc. will post -1.27 EPS for the current year.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.